Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical

CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan-Meier-reconstructed individual-level data

Summary

This meta-analysis investigated the efficacy of rechallenging with CDK4/6 inhibitors (CDK4/6i) after progression in patients with HR-positive, HER2-negative advanced/metastatic breast cancer. The study included 1396 patients from eight clinical trials, comparing CDK4/6i rechallenge plus endocrine therapy to endocrine therapy alone. Results indicated a significant improvement in median progression-free survival (PFS) of 5.8 months versus 3.7 months. A greater benefit was observed when switching to a different CDK4/6 inhibitor, particularly with abemaciclib, but no overall survival benefit was demonstrated.

Critical appraisal

This meta-analysis is crucial as it provides strong evidence supporting the rechallenge with CDK4/6 inhibitors in patients with HR-positive, HER2-negative advanced breast cancer after initial progression. It suggests that a rechallenge strategy, particularly with a switch to a different inhibitor like abemaciclib, can prolong progression-free survival, offering an additional therapeutic option in a setting where choices are limited. Although no overall survival benefit was observed, the improvement in PFS is clinically relevant for disease management and patient quality of life.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology